Takeda's dengue vaccine candidate (TAK-003) is safe and effective against dengue virus, according to part 1 of phase 3 clinical trial results published yesterday in the New England Journal of Medicine.
In its weekly flu update today, the US Centers for Disease Control and Prevention (CDC) reported the first pediatric flu deaths of the new season and noted that the nation's flu activity increased slightly last week but is still at low levels.
In one key category, under 7% of countries scored in the highest tier.
The Global Polio Eradication Initiative (GPEI) in its latest weekly update today noted new cases of polio in Pakistan, Angola, and Myanmar—all countries battling ongoing outbreaks of wild or vaccine-derived poliovirus.
The US Centers for Disease Control and Prevention (CDC) announced yesterday that the Pan American Health Organization (PAHO)/World Health Organization (WHO) have designated the CDC's Center for Global Health as a PAHO/WHO Collaborating Center for Biosafety and Biosecurity.
Genentech, part of the Roche Group, yesterday announced promising phase 3 trial findings for the use of one-dose baloxavir marboxil (Xofluza) to safely treat flu in children, according to results presented on Sep 1 during the Options X Congress in Singapore.
The National Institutes of Health (NIH) yesterday announced that researchers have started enrolling participants in a phase 1 clinical trial to evaluate immunogenicity and safety of two licensed seasonal flu vaccines given with and without novel adjuvants.
Emergent BioSolutions announced yesterday that the US Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) has exercised a contract option worth $261 million to buy doses of anthrax vaccine adsorbed with adjuvant (AV7909) for the Strategic National Stockpile (SNS).
An effort to reduce inappropriate antibiotic prescribing in New York City hospitals was associated with a modest decrease in prescribing for acute respiratory infections (ARIs), according to a study today in Infection Control and Hospital Epidemiology.
Treatment with neuraminidase inhibitors when patients are first admitted for flu reduced the length of hospitalization by 19%, according to a meta-analysis published yesterday in the Journal of Infectious Diseases.